Kezar Life Sciences Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
56
- Stock Symbol
-
KZR
- Share Price
-
$7.31
- (As of Thursday Closing)
Kezar Life Sciences General Information
Description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.
Contact Information
Website
www.kezarlifesciences.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Kezar Life Sciences Timeline
Kezar Life Sciences Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.31 | $6.90 | $4.30 - $18.55 | $501M | 68.5M | 661K | -$1.01 |
Kezar Life Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 295,394 | 773,406 | 97,265 | (1,918) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (63,538) | (53,149) | (41,406) | (36,041) |
| Net Income | (64,270) | (54,630) | (41,742) | (35,087) |
| Total Assets | 304,770 | 217,933 | 151,842 | 89,513 |
| Total Debt | 13,316 | 14,044 | 5,464 | 6,364 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kezar Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kezar Life Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kezar Life Sciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel sma
Drug Discovery
South San Francisco, CA
56
As of 2021
00000
000000000
00000
0000 0
ua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
0000000000000
Boston, MA
000
As of 0000
00000
0000
0000-00-00
000000&0
00000
000000
aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Heidelberg, Germany
000
As of 0000
00000
000000000
00000
Add Comparison
Kezar Life Sciences Competitors (61)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AVEO Oncology | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 000000000 | 00000 |
| 0000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
Kezar Life Sciences Patents
Kezar Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020228307-A1 | Thiazole derivatives as protein secretion inhibitors | Pending | 28-Feb-2019 | 0000000000 | |
| CA-3131930-A1 | Thiazole derivatives as protein secretion inhibitors | Pending | 28-Feb-2019 | 0000000000 | |
| EP-3930849-A1 | Thiazole derivatives as protein secretion inhibitors | Pending | 28-Feb-2019 | 0000000000 | |
| JP-2022522014-A | Thiazole derivative as a protein secretion inhibitor | Pending | 28-Feb-2019 | 0000000000 | |
| US-20220153732-A1 | Protein secretion inhibitors | Pending | 28-Feb-2019 | C07D417/14 |
Kezar Life Sciences Executive Team (9)
Kezar Life Sciences Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher Kirk Ph.D | Kezar Life Sciences | Chief Scientific Officer & Board Member | 000 0000 |
| Elizabeth Garner | Self | Board Member | 000 0000 |
| Franklin Berger | Self | Board Member | 000 0000 |
| Graham Cooper | Self | Chairman & Board Member | 000 0000 |
| John Fowler | Kezar Life Sciences | Chief Executive Officer & Board Member | 000 0000 |
Kezar Life Sciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kezar Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kezar Life Sciences ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
23.99 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 465
Rank
00.00
Percentile
